Cognivia is proud to announce that it has reached an important investment milestone. It is an innovative AI company. He is dedicated to redesigning pharmaceutical and biotechnological clinical research using cutting-edge artificial intelligence and machine learning algorithms

Cognivia's mission is to “quantify the power of the mind” in order to optimize and accelerate drug development programs. Indeed, Vesalius Biocapital IV, SFPIM (Société Fédérale de Participations et d'Investissements) and WE (Wallonie Entreprendre ) are committed to making strategic investments for support it. The funding will allow Cognivia to deploy its predictive clinical trial solutions that can decode the relationship between personality traits and patient behaviors, thereby accelerating the development of innovative treatments for patients globally

In reality, Vesalius Biocapital IV is a Luxembourg venture capital fund focused on first-class investments in health technology and biopharmaceuticals. SFPIM is the Belgian sovereign wealth fund, which provides strategic advice and financial support to Belgian companies. And WE contribute to the economic development of Wallonia by means of financing and support in various sectors

noted Cognivia is the first and only company to combine the quantification of patient psychology with artificial intelligence (AI) /machine learning (AM) in an effort to improve the measurement of therapeutic effectiveness in clinical trials - and beyond.